Regulations for the Sale of 
Viruses, Serums, Toxins 
and 
Analogous Products 
In the District of Columbia and 
in Interstate Traffic 
Approved October 12, 1940 
To supersede Regulations issued February 25, 1935 
and amendments thereto 
MISCELLANEOUS PUBLICATION No. 10 FEDERAL SECURITY AGENCY 
UNITED STATES PUBLIC HEALTH SERVICE 
Thomas Parhan, Surgeon General 
DIVISION OF SANITARY REPORTS AND STATISTICS 
Charles V. Akin, Assistant Surgeon General, Chief of Division 
UNITED STATES GOVERNMENT PRINTING OFFICE, WASHINGTON: 1941 
For sale by the Superintendent of Documents, Washington, D. C. 
Price 5 cents Federal Security Agency, * 
Washington, D. C., September 30, 1940. 
These regulations have been prepared by the undersigned board of 
officers pursuant to the authority contained in section 4 of the act of 
July 1, 1902, 32 Stat. 729 (U. S. C., title 42, sec. 145), entitled “An act 
to regulate the sale of viruses, serums, toxins, and analogous products 
in the District of Columbia, to regulate interstate traffic in said 
articles, and for other purposes.” They are hereby promulgated and 
will supersede the regulations issued February 25, 1935. 
Surgeon General, U. S. Army. 
Jas. C. Magee, 
Ross T. Mclntire, 
Surgeon General, U. S. Navy. 
Thomas Parran, 
Surgeon General, U. S. Public Health Service. 
Approved October 12, 1940. 
Wayne Coy, 
Acting Administrator, 
Federal Security Agency. REGULATIONS FOR THE SALE OF VIRUSES, SERUMS, 
TOXINS, AND ANALOGOUS PRODUCTS 
Pursuant to the authority contained in section 4 of the act of July 1, 
1902, 32 Stat. 729 (U.S.C., title 42, sec. 145), the following regulations 
for the sale of viruses, serums, toxins, and analogous products in the 
District of Columbia and in interstate traffic are hereby promulgated: 
LICENSES 
1. Licenses shall be issued, suspended, and revoked by the Adminis- 
trator of the Federal Security Agency, hereafter designated as “the 
Administrator,” upon the recommendation of the Surgeon General of 
the United States Public Health Service. 
2. Licenses shall be issued only after inspection of establishments 
and examination of the products for which license is desired. In the 
case of establishments already licensed, licenses for new products 
may, at the discretion of the Administrator, be granted without rein- 
spection of the establishment. License for new products shall not be 
granted withoilt satisfactory evidence of therapeutic or prophylactic 
efficiency. 
3. Whenever deemed necessary by the Surgeon General of the 
United States Public Health Service, the reports of inspection and 
laboratory examination shall be passed upon by the Sanitary Board 
of the United States Public Health Service. The board shall report 
its findings to the Surgeon General who shall forward the report, 
together with his recommendations, to the Administrator for action. 
4. Licenses shall be valid until suspended or revoked. The fol- 
lowing form of license is prescribed: 
This is to certify that of 
is hereby authorized under the provisions of “An act to regulate the sale of 
viruses, serums, toxins, and analogous products in the District of Columbia, to 
regulate interstate traffic in such articles, and for other purposes”, to engage 
in the manufacture, barter, and sale of such of these viruses, serums, toxins, 
and analogous products as are specified from time to time by the Administrator or 
Assistant Administrator of the Federal Security Agency, and of only such as have 
been so specified and for which license has not been suspended or revoked, in 
accordance with the above-mentioned act and regulations thereunder. 
Administrator. 
5. Licenses shall not be reissued without inspection of the establish- 
ments and laboratory examination of the products. The inspection 2 
and laboratory reports shall be passed upon by the Surgeon General 
of the United States Public Health Service in accordance with the 
provisions of paragraph 3. 
6. An establishment shall be subject to license when one or more 
of its products is held by the Administrator to be a virus, serum, toxin, 
or antitoxin, or a product analogous thereto and applicable to the 
prevention or cure of diseases of man. 
7. For the purpose of these regulations, viruses, serums, toxins, 
antitoxins, and analogous products applicable to the prevention or 
cure of diseases of man are referred to as biologic products and 
defined as follows: I. A virus is a product containing the minute 
living cause of an infectious disease. 11. A serum is the product 
obtained from the blood of an animal by removing the clot or clot 
components and the blood cells. 111. A toxin is a product contain- 
ing a soluble substance poisonous to laboratory animals or to man 
in doses of 1 milliliter or less of the product, and having the property, 
following the injection of nonfatal doses into an animal, of causing 
to be produced therein another soluble substance which specifically 
neutralizes the poisonous substance and which is demonstrable in 
the serum of the animal thus immunized. IV. An antitoxin is a 
product containing the soluble substance in the serum or other body 
fluid of an immunized animal which specifically neutralizes the toxin 
against which the animal is immune. V. A product is analogous (a) 
to a virus if prepared from a virus, including micro-organisms actu- 
ally or potentially virulent; {h) to a serum, if prepared from some 
protein constituent of the blood and intended for parenteral admin- 
istration; (c) to a toxin or antitoxin, if intended, by parenteral 
administration, for the prevention or treatment of disease through 
specific immunization. 
8. Instances of manufacture, importation, or sale of unlicensed 
products contrary to law, or of labeling unlicensed products as 
licensed or as if subject to license, shall be reported by officers of the 
Public Health Service, by State and local health authorities, by 
physicians, and by others to the Surgeon General of the United 
States Public Health Service for investigation or reference to the 
Department of Justice. 
9. In order to obtain a license for any biologic product, manufac- 
turers shall make application therefor to the Surgeon General of the 
United States Public Health Service on forms prescribed for the 
purpose. Inspectors shall be furnished with the original forms and 
shall certify thereon as to the condition of the establishment, with 
recommendations. 
10. Should important changes in personnel, method, equipment, or 
location be made by an establishment holding license, the manufac- 3 
turer shall immediately notify the Surgeon General of the United 
States Public Health Service and make notation on the form re- 
quired by paragraph 9 to be kept on file in the establishment. 
11. Biologic products imported from foreign countries will be re- 
fused entry by collectors of customs unless produced in an establish- 
ment holding an unsuspended and unrevoked license, or intended for 
examination prior to obtaining a license. Each foreign establish- 
ment holding license and importing biologic products into the United 
States shall be required to file the name and address of one or more 
representatives in the United States authorized by the establishment 
to distribute their products, and such representatives shall keep 
records of such distribution. 
12. The importation of smallpox vaccine from any foreign country 
into the United States is prohibited, except smallpox vaccine sent to 
the National Institute of Health of the United States Public Health 
Service, where tests shall be applied to demonstrate the absence of 
any other pathogenic virus. 
13. Each foreign importation of biologic products shall be accom- 
panied by two sample packages of each lot number contained in 
the shipment, and said samples shall be forwarded by the collector 
of customs at the port of entry to the National Institute of Health 
of the United States Public Health Service for examination. If 
separate samples are not found accompanying the shipment, samples 
shall be obtained from the shipment by the collector of customs and 
forwarded to the National Institute of Health of the United States 
Public Health Service. 
INSPECTION 
14. The inspections shall be made by an inspector or a board of 
inspectors detailed by the Administrator upon the recommendation 
of the Surgeon General of the United States Public Health Service. 
15. The inspectors shall be officers of the United States Public 
Health Service. 
16. Inspections shall be unannounced, unless special circumstances 
render this undesirable. 
17. It shall be the duty of the inspector to call upon the acting 
head of the establishment, stating the object of his visit. 
18. The inspectors shall examine all portions of the premises, 
appliances, stables, barns, warehouses, records, and the methods 
employed in actual operation. 
19. Inspectors are authorized to interrogate the proprietors and 
personnel of the establishment under oath. 
20. The inspectors shall investigate fully the methods of prepara- 
tion, storing, dispensing, and other details in the manufacture and 
sale of serums, viruses, toxins, and analogous products. 4 
21. The inspector shall carefully examine into location, construc- 
tion, or administration of establishments which would tend to en- 
danger the potency or purity of the products. 
22. Inspections for original licenses of an establishment need not be 
made until assurances are received that the establishment is in run- 
ning order and manufacturing the complete product for which license 
is desired. 
23. In case license is refused following an inspection, reinspection 
shall not be ordered until assurances have been received that the es- 
tablishment affected has corrected all the faulty conditions which 
were made the basis for the previous refusal of a license. 
24. In case faulty methods of preparation, faulty location, faulty 
construction, or faulty administration of establishments are ob- 
served during inspection, the inspector shall bring the same to the 
attention of the manufacturer, and shall forward a report of the con- 
ditions found, together with his recommendations, to the Surgeon 
General of the United States Public Health Service. 
25. Should the faulty conditions discovered during inspection or 
upon laboratory tests be found upon review by the Surgeon General 
of the United States Public Health Service to be of sufficient im- 
portance, the Surgeon General shall recommend to the Administrator 
that the license of the establishment be canceled or suspended. In 
case of suspension, if the said faulty conditions are not corrected within 
60 days he shall recommend that the said license be revoked, 
26. The fact of suspension or revocation of license, with causes 
therefor, may be published by the Administrator. 
27. The organization of a licensed establishment shall be such that 
the responsible head is actually in permanent control of the build- 
ings, grounds, equipment, and personnel; and good discipline shall 
prevail. 
28. In considering the license of an establishment, regard shall be 
had to the training and competence of the technical workers con- 
cerned. 
29. Permanent records shall be kept, with dates, of the various 
steps in the manufacture, testing, disposition, and distribution of 
each lot, so that at any time these steps may be traced by an inspector 
as regards any lot number. 
30. Laboratory cultures and other materials used in the produc- 
tion of biologic products shall be labeled and preserved in a safe and 
orderly manner. 
31. All work with spore-bearing pathogenic micro-organisms shall 
be so separated from other work, and the containers permanently 
so marked, as to avoid the possibility of contamination of products. 
MANUFACTURING ESTABLISHMENTS 5 
32. Laboratory procedures of a diagnostic nature shall, if con- 
ducted in an establishment, be entirely separate from those for the 
production of biologic products. 
33. Laboratories for the production of biologic products shall be 
efficient!}7 screened during the fly season. 
34. Sterilization and subsequent handling of containers, filling 
apparatus, and other materials which may come in contact with bio- 
logic products during manufacture shall be such as to insure the 
absence of living bacterial spores; except that the concentration of 
antitoxins may be conducted with scrupulous cleanliness rather than 
with absolute sterility. 
35. Records of the date, duration, and temperature of each sterili- 
zation shall be kept. Such records shall be made by means of auto- 
matic registering devices or by the personnel of the sterilizing room. 
36. Details of sanitary standards, methods of manufacturing and 
of testing, and methods of keeping records, may be communicated 
to manufacturers by inspectors. 
37. All containers used in the preparation of biologic products 
shall be of such construction as will readily permit inspection for 
cleanliness. 
38. The construction of bleeding rooms and rooms for vaccine 
animals shall be such as to permit thorough hosing down and cleaning. 
39. Hot water shall be provided in bleeding rooms and vaccine 
stables. 
40. Stable floors shall be so constructed and cared for as to insure 
cleanliness, and stables shall be well lighted and well ventilated. 
41. No manure shall be so stored as to permit the breeding of flies 
on the premises of any establishment. 
42. All personnel, animals, and equipment used in the production 
of hog-cholera serum shall be kept entirely separate from personnel, 
animals, and materials used in the production of biologic products 
for human use. 
43. Animals used in the production of biologic products shall be 
kept under competent daily inspection and preliminary quarantine 
by the establishment for a period of at least 7 days before use. Only 
healthy animals free from communicable disease shall be used; during 
the quarantine period those of the equine genus must be shown to be 
free from glanders, and those of the bovine genus must be shown to be 
free from tuberculosis. 
44. All horses used in the production of biologic products, except 
those horses which are actively immune to tetanus, shall be given 
not less than 500 units of tetanus antitoxin semimonthly, or 2,000 
units monthly. 
45. Necropsy records shall be kept of all animals which die or 
are killed after having been used in the production of biologic products. 6 
46. In case of actual or suspected infection with foot-and-mouth 
disease, glanders, tetanus, anthrax, gas gangrene, equine infectious 
anemia, or equine encephalomyelitis among animals used for the pro- 
duction of biologic products, the manufacturer shall immediately noti- 
fy the Surgeon General of the United States Public Health Service. 
47. Animals used for propagation of smallpox vaccine shall be 
thoroughly cleansed with soap and water at the beginning of the 
quarantine and at its conclusion. No part of the animal shall be 
vaccinated which is liable to be contaminated by feces. 
48. Preliminary to taking vaccine material from vaccinated ani- 
mals, said animals shall be killed or rendered insensible to pain. 
49. Each year at least two of the animals used in propagating 
smallpox vaccine of any one strain shall be kept for a period of 2 
weeks subsequent to the removal of the virus and observed sufficiently 
to demonstrate the absence of foot-and-mouth disease. At the 
termination of the period of observation in the case of these two ani- 
mals, and within 48 hours after taking the smallpox vaccine in the 
case of all other animals, a necropsy shall be made upon each animal, 
and permanent records kept of each necropsy, in which particular 
note shall be made of pathologic changes. 
50. All vaccine material from any animal having, or suspected of 
having, a communicable disease, other than vaccinia, shall be des- 
troyed. 
51. No animals used for the purpose of propagating smallpox 
vaccine shall be removed from the establishment prior to necropsy. 
52. The personnel who care for the vaccine animals shall be ex- 
cluded from horse stables and paddocks and from contact with horses 
while vaccine is being propagated. 
53. Extraneous materials shall not be stored or permitted in or 
about vaccine stables or operating rooms. 
54. Smallpox vaccine shall be furnished only in glass capillary 
tubes or in other glass containers. This shall not prohibit the in- 
closure in the same package, but separate from the virus, of a metal 
or glass instrument for inserting the virus. 
55. Capillary tubes for smallpox vaccine shall be filled mechanically 
in vacuum jars, and prior to filling shall be sterilized in the same 
containers which are used for filling. 
LABELING 
56. For purposes of labeling, the proper name of each product shall 
be that specified in the license. 
57. The proper name of each product must appear upon the out- 
side label in legible type and shall be given precedence in position and 
prominence over any other descriptive or trade name. 7 
58. In the case of products prepared by methods other than the 
usual or standard methods, the proper name used to designate the 
product in the license and on the labels shall be sufficiently descrip- 
tive to indicate such deviation. Should the species of animal used 
differ from that usually or originally employed, the name of the 
species shall be included as part of the proper name on the label. 
59. In case of products for which an official standard of potency has 
been adopted, the potency shall be expressed on the label in terms 
of the official standard. In case no official standard of potency has 
been adopted and no official test is made prior to the release of the 
product for sale, the label shall bear the following statement: “No 
U. S. standard of potency.” This provision shall not beheld to apply 
to smallpox vaccine, nor to rabies vaccine. 
60. The requirement that each package shall be marked with the 
date beyond which the contents cannot be expected beyond reason- 
able doubt to yield their specific results shall be held to be complied 
with if the label bears the date of manufacture or date of issue as 
defined in paragraphs 61 and 62 of these regulations, and a statement 
of the period in months or days from this date of manufacture or 
date of issue during which they may be expected to yield their specific 
results. 
61. Unless otherwise specifically provided as indicated in paragraph 
63, the date of manufacture shall be: (1) For products for which an 
official standard of potency exists, the last date of satisfactorily passing 
a potency test; (2) for products for which no official standard of po- 
tency exists, the date of removal from the animal in case of animal 
products, or the date of cessation of growth in the case of other products 
or (3) in the case of products used for specific desensitization, the 
date of extraction. 
62. Unless otherwise specifically provided as indicated in para- 
graph 63, the date of issue from cold storage may be accepted in lieu of 
the date of manufacture, provided the date of issue is not more than 
3 months after date of manufacture if the product is kept constantly 
at a temperature not exceeding 15° C., or not more than 6 months 
after the date of manufacture if the product is kept constantly at a 
temperature not exceeding 10° C., or not more than 1 year after the 
date of manufacture if the product is kept constantly at a temperature 
not exceeding 5° C., or not more than 2 years after date of manufacture 
if the product is kept constantly at a temperature not exceeding 0° C. 
63. Decisions shall be issued from time to time by the Surgeon 
General of the United States Public Health Service, regarding the 
dating of special products in accordance with tests made thereon. 
64. All labels affixed to containers shall bear the number of the 
lot of the product contained therein. 8 
65. The following items shall appear on the outside label: 
(1) Name of manufacturer. 
(2) Address of manufacturer. 
(3) License number. 
(4) Proper name of product. 
(5) Minimum potency of product. 
(6) “No U. S. standard of potency” if no such standard is established. 
(7) Lot number. 
(8) Date of manufacture or issue with period of potency; or the expiration date. 
66. In case a product manufactured by one establishment is sold 
by another, the name, address, license number, and lot number of 
the original manufacturer shall appear plainly on the label, provided 
the name of the second establishment may appear on the label as 
the selling agent. In case any part of the process, such as bottling, 
is performed by the second establishment, this establishment also 
must hold a license for the manufacture of the product; the names, 
addresses, and license numbers of both establishments must appear 
on the label, and the records of both establishments shall show 
plainly the degree of responsibility of each in the process of manu- 
facture. Labels bearing a license number shall appear only on 
packages of products for the manufacture of which a license is in 
force. 
EXAMINATION OF PRODUCTS 
67. Establishments shall furnish to the inspector and, on request, 
shall send to the National Institute of Health of the United States 
Public Health Service, adequate samples of products for examina- 
tion. 
68. Samples of special lots of products, or of all lots of particular 
products, may be required to be sent to the National Institute of 
Health of the United States Public Health Service for examination 
prior to being placed in interstate commerce or on sale in the District 
of Columbia. 
69. It shall be the duty of the Director of the National Institute 
of Health of the United States Public Health Service to test samples 
sent him by inspectors, and the result of this examination shall be 
given to the inspectors, who shall give this report due weight in 
making their recommendations. 
70. Biologic products offered for sale in the District of Columbia, 
or in interstate traffic, shall be obtained from time to time and 
examined at the National Institute of Health of the United States 
Public Health Service as to purity and potency and as to whether 
said products were properly labeled. 
71. In examining biologic products consideration shall be given 
to the character and safety of containers and to those materials 
accompanying them which are intended to facilitate administration 
of their contents. 9 
72. Official methods of testing, standards, and standard units 
shall be employed upon authorization of the Surgeon General of the 
United States Public Health Service. The official standards of po- 
tency for all forms of diphtheria antitoxin, tetanus antitoxin, botu- 
linus antitoxin type A, botulinus antitoxin type B, perfringens 
antitoxin, scarlet fever streptococcus antitoxin, vibrion septique 
antitoxin, antipneumococcic serum (types I, 11, V, VII, and VIII), 
antidysenteric serum (Shiga), staphylococcus antitoxin, histolyticus 
antitoxin, oedematiens antitoxin, and sordellii antitoxin shall be those 
distributed by the United States Public Health Service. 
73. Diphtheria antitoxin shall have a potency of not less than 
500 units per cubic centimeter if in liquid form, and not less than 
4,000 units per gram if in solid form. Tetanus antitoxin shall have 
a potency of not less than 400 units per cubic centimeter if in liquid 
form, and not less than 2,400 units per gram if in solid form. Scarlet 
fever streptococcus antitoxin shall have a potency of not less than 
400 units per cubic centimeter. 
74. Standard samples for comparison of products other than those 
mentioned in paragraph 72 may be distributed by the National 
Institute of Health, and the Director of the National Institute of 
Health is authorized to request manufacturers to forward such samples 
of their products for testing as may be required to insure safety and 
potency of products. 
75. Tests for potency, if applicable, shall be made after the com- 
pletion of all the processes of manufacture except filling the final 
containers. 
76. A sample of each lot of all products shall be tested for identity 
if such tost is applicable, and for safety, after the labels have been 
affixed to the final containers. 
77. No liquid serum shall contain more than 20 percent total solids, 
nor more than 0.5 percent of preservative. 
78. Products intended to be used intraspinally or intravenously 
shall be clear, free from excessive coloration, or excessive viscosity, 
and those to be used intraspinally shall contain not more than 0.35 
percent of preservative. 
79. Containers of products intended to be used intraspinally or 
intravenously shall be of such material that the presence of objection- 
able color or of sediment in the contents may be detected. 
80. Any lot of any product shall be subject to withdrawal and recall 
from the market, regardless of dating, upon the discovery of lack of 
purity, potency, or safety, or if the product is found to be subject to 
undue deterioration. Upon the discovery of such information the 
same shall be communicated to the manufacturer of the product in 
question and the identification of said product may be made public 
by the Administrator, [Public—No. 244] 
AN ACT To regulate the sale of viruses, serums, toxins, and analogous products 
;n the District of Columbia, to regulate interstate traffic in said articles, and 
for other purposes. 
Be it enacted by the Senate and House oj Representatives of the 
United States of America in Congress assembled, That from and after 
six months after the promulgation of the regulations authorized by 
section 4 of this act no person shall sell, barter, or exchange, or offer 
for sale, barter, or exchange in the District of Columbia, or send, 
carry, or bring for sale, barter, or exchange from any State, Territory, 
or the District of Columbia into any State, Territory, or the District 
of Columbia, or from any foreign country into the United States, or 
from the United States into any foreign country, any virus, thera- 
peutic serum, toxin, antitoxin, or analogous product applicable to the 
prevention and cure of diseases of man, unless (a) such virus, serum, 
toxin, antitoxin, or product has been propagated and prepared at an 
establishment holding an unsuspended and unrevoked license, issued 
by the Secretary of the Treasury as hereinafter authorized, to propa- 
gate and prepare such virus, serum, toxin, antitoxin, or product for 
sale in the District of Columbia, or for sending, bringing, or carrying 
from place to place aforesaid; nor (b) unless each package of such virus, 
serum, toxin, antitoxin, or product is plainly marked with the proper 
name of the article contained therein, the name, address, and license 
number of the manufacturer, and the date beyond which the contents 
cannot be expected beyond reasonable doubt to yield their specific 
results: Provided, That the suspension or revocation of any license 
shall not prevent the sale, barter, or exchange of any virus, serum, 
toxin, antitoxin, or product aforesaid which has been sold and delivered 
by the licentiate prior to such suspension or revocation, unless the 
owner or custodian of such virus, serum, toxin, antitoxin, or product 
aforesaid has been notified by the Secretary of the Treasury not to 
sell, barter, or exchange the same. 
Sec. 2. That no person shall falsely label or mark any package or 
container of any virus, serum, toxin, antitoxin, or product aforesaid, 
nor alter any label or mark on any package or container of any virus, 
serum, toxin, antitoxin, or product aforesaid so as to such 
label or mark. 
Sec. 3. That any officer, agent, or employee of the Treasury De- 
partment duly detailed by the Secretary of the Treasury for that 
purpose, may, during all reasonable hours, enter and inspect any 
establishment for the propagation and preparation of any virus, 
serum, toxin, antitoxin, or product aforesaid for sale, barter, or ex- 11 
change in the District of Columbia, or to be sent, carried, or brought 
from any State, Territory, or the District of Columbia into any other 
State or Territory or the District of Columbia, or from the United 
States into any foreign country, or from any foreign country into the 
United States. 
Sec. 4. That the Surgeon General of the Army, the Surgeon Gen- 
eral of the Navy, and the supervising Surgeon General of the Marine 
Hospital Service be, and they are hereby, constituted a board with 
authority, subject to the approval of the Secretary of the Treasury, 
to promulgate from time to time such rules as may be necessary in the 
judgment of said board to govern the issue, suspension, and revoca- 
tion of licenses for the maintenance of establishments for the propa- 
gation and preparation of viruses, serums, toxins, antitoxins, and 
analogous products, applicable to the prevention and cure of diseases 
of man, intended for sale in the District of Columbia, or to be sent, 
carried, or brought for sale from any State, Territory, or the District 
of Columbia into any other State, Territory, or the District of 
Columbia, or from the United States into any foreign country, or 
from any foreign country into the United States: Provided, That 
all licenses issued for the maintenance of establishments for the 
propagation, and preparation in any foreign country of any virus, 
serum, toxin, antitoxin, or product aforesaid for sale, barter, or 
exchange in the United States, shall be issued upon condition that 
the licentiates will permit the inspection of the establishments where 
said articles are propagated and prepared, in accordance with section 
3 of this act. 
Sec. 5. That the Secretary of the Treasury be, and he is hereby, 
authorized and directed to enforce the provisions of this act and of 
such rules and regulations as may be made by authority thereof; to 
issue, suspend, and revoke licenses for the maintenance of establish- 
ments aforesaid, and to detail for the discharge of such duties such 
officers, agents, and employees of the Treasury Department as may 
in his judgment be necessary. 
Sec. 6. That no person shall interfere with any officer, agent, or 
employee of the Treasury Department in the performance of any 
duty imposed upon him by this act or by regulations made by 
authority thereof. 
Sec. 7. That any person who shall violate, or aid or abet in violat- 
ing, any of the provisions of this act shall be punished by a fine not 
exceeding five hundred dollars or by imprisonment not exceeding one 
year, or by both such fine and imprisonment in the discretion of the 
court. 
Sec. 8. That all acts and parts of acts inconsistent with the 
provisions of this act be, and the same are hereby, repealed. 
Approved, July 1, 1902,